Evidence map›Paper›PMID 36016158›Full record

ArticleVaccines2022

Attitudes toward Receiving COVID-19 Booster Dose in the Middle East and North Africa (MENA) Region: A Cross-Sectional Study of 3041 Fully Vaccinated Participants.

Mohamed Abouzid, Alhassan Ali Ahmed, Dina M El-Sherif, Wadi B Alonazi, Ahmed Ismail Eatmann, Mohammed M Alshehri, Raghad N Saleh, Mareb H Ahmed, Ibrahim Adel Aziz, Asmaa E Abdelslam and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 7 countries.

Mohamed AbouzidDepartment of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland.ORCID 0000-0002-8917-671X
Alhassan Ali AhmedDoctoral School, Poznan University of Medical Sciences, 61-701 Poznan, Poland.ORCID 0000-0003-1912-0195
Dina M El-SherifNational Institute of Oceanography and Fisheries (NIOF), Cairo 11694, Egypt.ORCID 0000-0002-8798-9004
Wadi B AlonaziHealth Administration Department, College of Business Administration, King Saud University, P.O. Box 71115, Riyadh 11587, Saudi Arabia.ORCID 0000-0002-3850-4437
Ahmed Ismail EatmannDepartment of Cell Biophysics, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University in Kraków, 31-007 Krakow, Poland.
Mohammed M AlshehriPhysical Therapy Department, Jazan University, P.O. Box 114, Jazan 45142, Saudi Arabia.
Raghad N SalehOral Health and Promotion Unit, Faculty of Dentistry, Al-Quds University, Jerusalem P.O. Box 89, Palestine.ORCID 0000-0003-0834-1494
Mareb H AhmedDental College, AlNoor University College, Bartella 46476, Iraq.
Ibrahim Adel AzizFaculty of Medicine, Al Neelain University, Khartoum P.O. Box 12702, Sudan.
Asmaa E AbdelslamFaculty of Medicine for Girls, Al-Azhar University, Cairo 71524, Egypt.
Asmaa Abu-Bakr OmranFaculty of Medicine for Girls, Al-Azhar University, Cairo 71524, Egypt.
Abdallah A OmarDepartment of Pharmaceutical Services and Sciences, Children's Cancer Hospital Egypt (CCHE-57357), Cairo 11617, Egypt.
Mohamed A GhorabWildlife Toxicology Laboratory, Department of Animal Science, Institute for Integrative Toxicology (IIT), Michigan State University, East Lansing, MI 48824, USA.ORCID 0000-0001-7880-965X
Sheikh Mohammed Shariful IslamInstitute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Melbourne, VIC 3125, Australia.ORCID 0000-0001-7926-9368
Al-Azhar University · EGPoznan University of Medical Sciences · PLAl-Neelain University · SDAl-Quds University · PSChildren Cancer Hospital · EGDeakin University · AUJagiellonian University · PLJazan University · SAKing Saud University · SAMichigan State University · USNational Institute of Oceanography and Fisheries · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 vaccines are crucial to control the pandemic and avoid COVID-19 severe infections. The rapid evolution of COVID-19 variants such as B.1.1.529 is alarming, especially with the gradual decrease in serum antibody levels in vaccinated individuals. Middle Eastern countries were less likely to accept the initial doses of vaccines. This study was directed to determine COVID-19 vaccine booster acceptance and its associated factors in the general population in the MENA region to attain public herd immunity. We conducted an online survey in five countries (Egypt, Iraq, Palestine, Saudi Arabia, and Sudan) in November and December 2021. The questionnaire included self-reported information about the vaccine type, side effects, fear level, and several demographic factors. Kruskal−Wallis ANOVA was used to associate the fear level with the type of COVID-19 vaccine. Logistic regression was performed to confirm the results and reported as odds ratios (ORs) and 95% confidence intervals. The final analysis included 3041 fully vaccinated participants. Overall, 60.2% of the respondents reported willingness to receive the COVID-19 booster dose, while 20.4% were hesitant. Safety uncertainties and opinions that the booster dose is not necessary were the primary reasons for refusing the booster dose. The willingness to receive the booster dose was in a triangular relationship with the side effects of first and second doses and the fear (p < 0.0001). Females, individuals with normal body mass index, history of COVID-19 infection, and influenza-unvaccinated individuals were significantly associated with declining the booster dose. Higher fear levels were observed in females, rural citizens, and chronic and immunosuppressed patients. Our results suggest that vaccine hesitancy and fear in several highlighted groups continue to be challenges for healthcare providers, necessitating public health intervention, prioritizing the need for targeted awareness campaigns, and facilitating the spread of evidence-based scientific communication.

Indexed as

coronavirusmRNA vaccinesSARS-CoV-2vaccine hesitancyvector vaccines

Identifiers

PMID36016158
PMCPMC9414713
OpenAlexW4291670774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.